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ABSTRACT
Introduction: Finasteride is one of the most
common drugs used in androgenetic alopecia.
The literature discusses the sexual side effects of
the drug; however, in practice there is little
evidence to support this. The aim of the present
study was to investigate the sexual dysfunction
in patients taking finasteride 1 mg for
androgenetic alopecia.
Methods: A questionnaire, based on the
International Index of Erectile Function, was
given to approximately 586 patients with
androgenetic alopecia who were being treated
with finasteride 1 mg for an average of
16 weeks. These patients were compared to an
age-related control group who were attending
the Dermatology Out Patients Department for
various other skin ailments not related to hair
disorders.
Results: Statistical analysis of the results
showed no significant difference in the scores
between patients taking finasteride and the
control group.
Conclusion: Analysis showed no significant
difference in sex-related problems with that of
patients taking finasteride and age matched
controls, suggesting that sex-related issues are
not a side effect of finasteride.
Keywords: Androgenetic alopecia; Erectile
dysfunction; Finasteride; Loss of libido; Male
pattern baldness
INTRODUCTION
Finasteride 1 mg is used successfully all over the
world for the treatment of androgenetic
alopecia in male pattern baldness [1]. It is
approved in the USA and many other
countries. Various clinical trials have
established finasteride’s efficacy in adult men
with predominant vertex, anterior and
midscalp region [2, 3]. On average, less than
2% of patients show side effects to the drug [4].
Common side effects are loss of libido, erectile
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dysfunction and decreased ejaculate volume.
These side effects were found in less than 0.5%
of patients [11].
To assess the huge difference [2, 11] in
reporting the side effects, we conducted a
2-year randomized, questionnaire-based
research study on patients receiving finasteride
1 mg tablets for androgenetic alopecia. For this,
we used a questionnaire based on the
International Index of Erectile Function (IIEF)
(Supplementary Table 1) [5]. This checks five
domains: erectile function, orgasmic function,
sexual desire, intercourse satisfaction and
overall sexual satisfaction. A higher IIEF score
indicates better sexual function and low score
(below 25) indicates erectile dysfunction.
The aim of the present study was to evaluate
an age-matched comparison and evaluation of
sexual function in patients treated by
finasteride 1 mg for early androgenetic
alopecia by using IIEF.
METHODS
We randomized approximately 586 subjects in a
simple random sampling method. Inclusion
criteria were age 18–40 years, who came for an
outpatient consultation for male pattern
androgenetic alopecia, which was diagnosed
using the Norwood–Hamilton’s grading of
male pattern alopecia with grade 3 to 5 on
treatment with finasteride 1 mg, with good
physical health. Exclusion criteria were
patients being treated for various other causes
of hair loss other than androgenetic alopecia.
Those selected patients were briefed about the
IIEF questionnaire and, with their consent, the
questionnaire was provided for completion. A
mean duration of approximately 16 weeks of
medication was consumed by the patients at the
time of answering the questionnaire. Our
controls were 586 patients who attended
outpatient consultation for various other
non-hair related diseases such as Psoriasis
vulgaris, Lichen planus, allergic contact
dermatitis, irritant contact dermatitis, nail
disorders, etc.
The resultant scores of erectile function
domain and IIEF domain of both the study
group taking Finasteride 1 mg and their
age-wise control group were analyzed with the
IBM Software package (SPSS Statistics, NY, USA).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Both the study group and controls were asked to
answer the IIEF questionnaire anonymously to





















Fig. 1 Age controlled 3D graphs showing the scores of
domain in erectile function (a) and international index of
erectile function domain (b) in patients on Finasteride and
their controls with age and scores both depicted in Y axis
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results were compared in an age-wise manner.
Comparing the age-wise finasteride-consuming
patients and the control group, there was no
statistical difference between the groups
regarding their sexual function in total IIEF
score or in any of the five domains mentioned.
The age-controlled graphs (Fig. 1) show the
scores in the erectile function domain (A) and
international index of erectile function domain
(B) in patients on finasteride and their controls.
DISCUSSION
The main mechanism in androgenetic alopecia
is miniaturization of hair follicles from terminal
to vellus hair [6] due to the effect of androgen,
especially dihydrotestosterone. Testosterone is
converted by 5 alpha reductase to 5 alpha
dihydrotestosterone, which is five times more
potent than testosterone [8]. This
dihydrotestosterone binds to the androgen
receptors of the genetically marked hair
follicle and leads to miniaturization of that
hair follicle. This also reduces the rate of hair
growth [7].
Finasteride is an azasteroid type 2 isoenzyme,
5 alpha reductase inhibitor, which inhibits
dihydrotestosterone conversion from
testosterone [8]. This type 2 isoenzyme is
present in the hair follicles and its activity is
important in controlling the end organ
hyper-reactivity causing androgenetic alopecia
[8]. Testosterone is responsible for sexual
function after puberty, but not by
dihydrotestosterone. Observation of eunuchs
and prepubertal boys highlighted the role of
testosterone in the induction of androgenetic
alopecia [9]. Therefore, it is evident that
finasteride should not cause any side effects,
relating to sexual health, as there will be no
decrease in the quantity or quality of the
testosterone level. However, clinical trials
conducted by Leyden et al. [10] and Kaufman
et al. [2] resulted in 2% of patients experiencing
sexual side effects such as the loss of libido,
erectile dysfunction and decreased ejaculate
volume [4].
In this study, patients taking Finasteride
1 mg for androgenetic alopecia and the
control group were provided with the IIEF
questionnaire and their responses analyzed.
The results indicated that erectile and sexual
function was not reduced compared to the
controls. So, not only theoretically, finasteride
was found to be a comparatively safe drug in
this Indian male population. This study was
conducted in the Indian context on the basis of
the IIEF [5] and the European study by Tosti
et al. [11]. The present study was limited to
Indian patients. Further studies should be
conducted in a multi-center, double-blind
manner.
CONCLUSION
In both our study and the study conducted by
Tosti et al. [11], sexual and erectile function of
those subjects who were orally treated with
finasteride was not reduced compared with
their age-related controls.
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